New data shed light on the best strategies for managing patients who develop interstitial lung disease while being treated ...

The study will be carried out in partnership with The GOG Foundation and the European Network of Gynaecological Oncological ...

With a median progression-free survival of more than three years, the DESTINY-Breast09 results show trastuzumab deruxtecan combined with pertuzumab has the potential to become a new first-line ...

But the aluminum or steel labels withstand this abuse, even if the plants themselves sometimes don’t, and the outdoor-grade label tape stays legible. (The Willott Iris Garden has occasional ...

One user added an additional tip, noting: "if you fill the jar with boiling/very hot water, it usually melts the glue so you can peel the label in one pull." Many commenters were thankful to have a ...

As such, "the combination of T-DXd and pertuzumab may represent a new first-line standard of care for patients with ...

We conducted an international, randomized, phase 3 trial comparing second-line trastuzumab deruxtecan at a dose of 6.4 mg per kilogram of body weight with ramucirumab plus paclitaxel in patients ...

Second-line trastuzumab deruxtecan-nxki significantly improved outcomes for advanced gastric cancers compared with paclitaxel plus ramucirumab. Confirmation of HER2 status after first-line ...

“Trastuzumab deruxtecan is approved for patients with metastatic HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma who received a prior trastuzumab-based regimen based on ...

The new law will allow doctors and medical providers to request that their names not appear on the label for such drugs. Instead, the label would list the name of the health care facility that employs ...